IB Neuro

Imaging Biometrics

Key Features

Automated quantification of DSC perfusion parameters

General Information

Product name

IB Neuro

Company

Imaging Biometrics

Subspeciality

Neuro

Modality

CT, MR

Disease targeted

Brain tumors, stroke

Main task

Not specified

Technical Specifications

Population

All MR and CT neuro perfusion exams

Patient population age

Not specified

Input

GRE-EPI

Input format

DICOM

Output

RGB, monochrome (quantitative), fused overlays, automated AIF information, and reporting of DSC parameter maps

Output format

Quantitative DICOM

Integration

Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Plugin application to OsiriX environments, Stand-alone third party application

Deployment

Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker)

Trigger for analysis

Automatically, Etc., Image upload, On demand, Right after the image acquisition, Triggered by a user through e.g. a button click

Processing time

3 - 10 seconds

Regulatory Information

CE Certification

Pathway:

MDD

Class:

Class I

Verified by Health AI Register

FDA Certification

Pathway:

510(k) cleared

Class:

Class II

Verified by Health AI Register

Other certifications

Not specified

Market Presence

On market since

05-2018

AI Platforms

Bayer Pharmaceuticals, Blackford Analysis, Medimsight, Tempus, TeraRecon

Resellers

Aycan medical systems, CorTechs Labs, Pixmeo, QMENTA

Countries present

Not specified

Paying clinical customers

Not specified

Research/test users

Not specified

Pricing Information

Pricing model

One-off payment with service contract, Pay-per-use, Subscription

Based on

Number of analyses, Number of installations

Evidence & Research

Peer-Reviewed Papers

Peer-Reviewed

View

How to evaluate perfusion imaging in post-treatment glioma: a comparison of three different analysis methods

Peer-Reviewed

View

Arterial Spin-Labeling and DSC Perfusion Metrics Improve Agreement in Neuroradiologists’ Clinical Interpretations of Posttreatment High-Grade Glioma Surveillance MR Imaging—An Institutional Experience

Peer-Reviewed

View

Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma

Peer-Reviewed

View

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial

Peer-Reviewed

View

Performance of Standardized Relative CBV for Quantifying Regional Histologic Tumor Burden in Recurrent High-Grade Glioma: Comparison against Normalized Relative CBV Using Image-Localized Stereotactic Biopsies